武亚鑫,赵敏,李浩然,王珂

• 1:吉林大学第二医院呼吸与危重症医学科

摘要(Abstract)：

肺炎克雷伯菌（Klebsiella pneumoniae,KP）是临床常见的条件致病菌，可引起呼吸系统、泌尿系统、循环系统等多部位的感染，尤其是对免疫力较低下的人群更易感。由于大量广谱抗生素的使用，多重耐药的肺炎克雷伯菌在全球范围内广泛流行，碳青霉烯类抗生素曾被认为是对抗细菌的“最后防线”，然而随着耐碳青霉烯类肺炎克雷伯菌（carbapenem-resistant Klebsiella pneumoniae,CRKP）在各地被发现，在近十几年间CRKP在全球范围内广泛传播，其耐药机制复杂且尚未明确，已知的主要机制是产生各种水解药物的酶。现就CRKP的流行现状、高危因素、耐药机制及诊疗进展进行阐述。

关键词(KeyWords)： 肺炎克雷伯菌;碳青霉烯耐药;耐药机制;诊疗进展

Abstract:

Keywords:

基金项目(Foundation): 吉林省科技发展计划项目（20200708083YY）

作者(Author): 武亚鑫,赵敏,李浩然,王珂

DOI: 10.13463/j.cnki.cczyy.2023.01.022

参考文献(References)：

• [1] HAN J H, GOLDSTEIN E J, WISE J, et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae in a network of long-term acute care hospitals[J]. Clinical Infectious Diseases:an official publication of the Infectious Diseases Society of America, 2017, 64(7):839-844.
• [2] GUDUCUOGLU H, GURSOY N C, YAKUPOGULLARI Y, et al. Hospital outbreak of a colistin-resistant, NDM-1-and OXA-48-producing Klebsiella pneumoniae:High mortality from pandrug resistance[J]. Microbial Drug Resistance(Larchmont, NY), 2018, 24(7):966-972.
• [3] MACKENZIE F M, FORBES K J, DORAI-JOHN T,et al. Emergence of a carbapenem-resistant Kiebsiella pneumoniae[J]. The Lancet, 1997, 350(9080):783.
• [4] LIU P, LI X, LUO M, et al. Risk factors for carbapenemresistant Klebsiella pneumoniae infection:a metaanalysis[J]. Microbial Drug Resistance(Larchmont, NY),2018, 24(2):190-198.
• [5] WEI Z Q, DU X X, YU Y S, et al. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China[J].Antimicrobial Agents and Chemotherapy, 2007,51(2):763-765.
• [6] GAO L, LV Y, LI Y. Analysis of the drug resistance of carbapenem-resistant Klebsiella pneumoniae in the China Antimicrobial Resistance Surveillance Trial Program,2007-2018[J]. Microbial Drug Resistance(Larchmont,NY), 2020, 26(8):944-950.
• [7]全国细菌耐药监测网2014—2019年耐碳青霉烯类肺炎克雷伯菌流行病学变迁[J].中国感染控制杂志, 2021,20(2):175-179.
• [8]胡付品,朱德妹,汪复,等. 2015年CHINET细菌耐药性监测[J].中国感染与化疗杂志, 2016, 16(6):685-694.
• [9]胡付品,郭燕,朱德妹,等. 2016年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志, 2017, 17(5):481-491.
• [10]胡付品,郭燕,朱德妹,等. 2017年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志[J]. 2018, 18(3):241-251.
• [11]胡付品,郭燕,朱德妹,等. 2018年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志, 2020, 20(1):1-10.
• [12]BAND V I, SATOLA S W, BURD E M, et al.Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection[J]. mBio,2018, 9(2):e02448-17.
• [13]NGUYEN T N T, NGUYEN P L N, LE N T Q, et al.Emerging carbapenem-resistant Klebsiella pneumoniae sequence type 16 causing multiple outbreaks in a tertiary hospital in southern Vietnam[J]. Microbial Genomics,2021, 7(3).
• [14]ZHOU K, XIAO T, DAVID S, et al. Novel subclone of carbapenem-resistant Klebsiella pneumoniae sequence type 11 with enhanced virulence and transmissibility,China[J]. Emerging Infectious Diseases, 2020, 26(2):289-297.
• [15]RUPP M E, FEY P D. Extended spectrum beta-lactamase(ESBL)-producing Enterobacteriaceae:considerations for diagnosis, prevention and drug treatment[J]. Drugs, 2003,63(4):353-365.
• [16]YIGIT H, QUEENAN A M, ANDERSON G J, et al.Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae[J]. Antimicrobial Agents and Chemotherapy,2001, 45(4):1151-1161.
• [17]ANTONIADOU A, KONTOPIDOU F, POULAKOU G,et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients:first report of a multiclonal cluster[J]. Journal of Antimicrobial Chemotherapy, 2007, 59(4):786-790.
• [18]ARATO V, RASO M M, GASPERINI G, et al.Prophylaxis and treatment against Klebsiella pneumoniae:current insights on this emerging anti-microbial resistant global threat[J]. International Journal of Molecular Sciences, 2021, 22(8).
• [19]GU D, DONG N, ZHENG Z, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital:a molecular epidemiological study[J]. The Lancet Infectious Diseases,2018, 18(1):37-46.
• [20]LI J, WANG J, YANG Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China:a retrospective analysis[J]. Antimicrobial Resistance and Infection Control, 2020, 9(1):153.
• [21]MONTRUCCHIO G, CORCIONE S, SALES G, et al.Carbapenem-resistant Klebsiella pneumoniae in ICUadmitted COVID-19 patients:Keep an eye on the ball[J].Journal of Global Antimicrobial Resistance, 2020, 23:398-400.
• [22]LIN Z, YU J, LIU S, et al. Prevalence and antibiotic resistance of Klebsiella pneumoniae in a tertiary hospital in Hangzhou, China, 2006-2020[J]. Journal of International Medical Research, 2022, 50(2):3000605221079761.
• [23]ZHU W M, YUAN Z, ZHOU H Y. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients:a systematic review and meta-analysis[J]. Antimicrobial Resistance and Infection Control, 2020, 9(1):23.
• [24]GIDDINS M J, MACESIC N, ANNAVAJHALA M K,et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in bla(KPC-2)-harboring Klebsiella pneumoniae sequence t y p e 3 0 7 i s o l a t e s[J]. A n t i m i c r o b i a l A g e n t s a n d Chemotherapy, 2018, 62(3):e02101-17.
• [25]GARCíA-BETANCUR J C, APPEL T M, ESPARZA G,et al. Update on the epidemiology of carbapenemases in Latin America and the Caribbean[J]. Expert Review of Anti-infective Therapy, 2021, 19(2):197-213.
• [26]QIN X, WU S, HAO M, et al. The colonization of carbapenem-resistant Klebsiella pneumoniae:epidemiology, resistance mechanisms, and risk factors in patients admitted to intensive care units in China[J].The Journal of Infectious Diseases, 2020, 221(Suppl 2):S206-S214.
• [27]KOBAYASHI S D, PORTER A R, FREEDMAN B, et al.Antibody-mediated killing of carbapenem-resistant ST258Klebsiella pneumoniae by human neutrophils[J]. mBio,2018, 9(2).
• [28]HU Y, LIU C, SHEN Z, et al. Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China,2008-2018[J]. Emerging Microbes&Infections, 2020,9(1):1771-1779.
• [29]WU W, FENG Y, TANG G, et al. NDM metallo-β-lactamases and their bacterial producers in health care settings[J]. Clinical Microbiology Reviews, 2019,32(2):e00297-18.
• [30]PAPP-WALLACE K M. The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections[J]. Expert Opinion on Pharmacotherapy, 2019, 20(17):2169-2184.
• [31]XU J, ZHAO Z, GE Y, et al. Unravelling the genome sequence of NDM-1 and KPC-2 co-producing Klebsiella p n e u m o n i a e S T 11 i s o l a t e d f r o m a b l o o d s t r e a m infection[J]. Journal of Global Antimicrobial Resistance,2020, 20:339-341.
• [32]LIU L, FENG Y, TANG G, et al. Carbapenem-resistant isolates of the Klebsiella pneumoniae complex in western China:The common ST11 and the surprising hospitalspecific types[J]. Clinical Infectious Diseases, 2018,67(suppl_2):S263-S265.
• [33]SHERCHAN J B, TADA T, SHRESTHA S, et al.Emergence of clinical isolates of highly carbapenemresistant Klebsiella pneumoniae co-harboring bla(NDM-5)and bla(OXA-181 or-232)in Nepal[J]. International Journal of Infectious Diseases, 2020, 92:247-252.
• [34]BAHMANI N. Detection of VIM-1, VIM-2 and IMP-1 metallo-β-lactamase genes in Klebsiella pneumoniae isolated from clinical samples in Sanandaj, Kurdistan,west of Iran[J]. Iranian Journal of Microbiology, 2019,11(3):225-231.
• [35]JORGENSEN S C J, RYBAK M J. Meropenem and vaborbactam:stepping up the battle against carbapenemresistant enterobacteriaceae[J]. Pharmacotherapy, 2018,38(4):444-461.
• [36]PITOUT J D D, PEIRANO G, KOCK M M, et al. The global ascendency of OXA-48-type carbapenemases[J].Clinical Microbiology Reviews, 2019, 33(1).
• [37]ESCANDóN-VARGAS K, REYES S, GUTIéRREZ S, et al. The epidemiology of carbapenemases in Latin America and the Caribbean[J]. Expert Review of Anti-infective Therapy, 2017, 15(3):277-297.
• [38]王青,李耘,郑波.中国2017-2018年耐碳青霉烯类肺炎克雷伯菌药物敏感性及耐药基因分析[J].中国感染控制杂志, 2021, 20(5):437-442.
• [39]NISHIDA S, ONO Y. Genomic analysis of a pan-resistant Klebsiella pneumoniae sequence type 11 identified in Japan in 2016[J]. International Journal of Antimicrobial Agents, 2020, 55(4):105854.
• [40]HUANG P H, CHENG Y H, CHEN W Y, et al. Risk factors and mechanisms of in vivo emergence of colistin resistance in carbapenem-resistant Klebsiella pneumoniae[J]. International Journal of Antimicrobial Agents, 2021, 57(6):106342.
• [41]FRITZENWANKER M, IMIRZALIOGLU C, HEROLD S,et al. Treatment options for carbapenem-resistant gramnegative infections[J]. Deutsches Arzteblatt International,2018, 115(20-21):345-352.
• [42]YANG Y, YANG Y, CHEN G, et al. Molecular characterization of carbapenem-resistant and virulent plasmids in Klebsiella pneumoniae from patients with bloodstream infections in China[J]. Emerging Microbes&Infections, 2021, 10(1):700-709.
• [43]POURNARAS S, KOUMAKI V, SPANAKIS N, et al. Current perspectives on tigecycline resistance in Enterobacteriaceae:susceptibility testing issues and mechanisms of resistance[J]. International Journal of Antimicrobial Agents, 2016, 48(1):11-18.
• [44]JIN X, CHEN Q, SHEN F, et al. Resistance evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11 during treatment with tigecycline and polymyxin[J]. Emerging Microbes&Infections, 2021,10(1):1129-1136.
• [45]ZHANG P, SHI Q, HU H, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China[J]. Clinical Microbiology and Infection, 2020, 26(1):124.e1-.e4.
• [46]VENDITTI C, BUTERA O, MELEDANDRI M, et al.Molecular analysis of clinical isolates of ceftazidimeavibactam-resistant Klebsiella pneumoniae[J]. Clinical Microbiology and Infection, 2021, 27(7):1040.e1-.e6.
• [47]GALANI I, ANTONIADOU A, KARAISKOS I, et al. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam[J]. Clinical Microbiology and Infection, 2019, 25(6):763.e5-.e8.
• [48]FENG Y, LU Y, YAO Z, et al. Carbapenem-resistant hypervirulent Klebsiella pneumoniae of sequence type36[J]. Antimicrobial Agents and Chemotherapy, 2018,62(7):62.
• [49]GU D, DONG N, ZHENG Z, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital:a molecular epidemiological study[J]. The Lancet Infectious Diseases,2018, 18(1):37-46.
• [50]AHMED M, YANG Y, YANG Y, et al. Emergence of hypervirulent carbapenem-resistant Klebsiella pneumoniae coharboring a bla(NDM-1)-carrying virulent plasmid and a bla(KPC-2)-carrying plasmid in an Egyptian hospital[J]. mSphere, 2021, 6(3).
• [51]吴正海,刘海洋,陈华乐,等.多粘菌素B联合不同抗菌药物对耐碳青霉烯类肺炎克雷伯菌的体外抗菌作用[J].温州医科大学学报, 2017, 47(12):898-901.
• [52]GENG T T, XU X, HUANG M. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections:A retrospective cohort study[J]. Medicine, 2018, 97(8):e9961.
• [53]ZHANG W, GUO Y, LI J, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae[J].Antimicrobial Resistance and Infection Control, 2018,7:142.
• [54]PRAGASAM A K, VEERARAGHAVAN B, SHANKAR B A, et al. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms:Lessons learnt from in vitro study[J]. Indian Journal of Medical Microbiology, 2019, 37(1):34-41.
• [55]NATH S, MOUSSAVI F, ABRAHAM D, et al. In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae[J].Journal of Antimicrobial Chemotherapy, 2018, 73(2):431-436.
• [56]BORJAN J, MEYER K A, SHIELDS R K, et al. Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis[J].International Journal of Antimicrobial Agents, 2020,55(1):105852.
• [57]OJDANA D, GUTOWSKA A, SACHA P, et al. Activity of ceftazidime-avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae[J].Microbial Drug Resistance(Larchmont, NY), 2019,25(9):1357-1364.
• [58]BARNES M D, TARACILA M A, GOOD C E, et al.Nacubactam enhances meropenem activity against carbapenem-resistant Klebsiella pneumoniae producing KPC[J]. Antimicrobial Agents and Chemotherapy, 2019,63(8).
• [59]ZHAO D, LI H, YUE C, et al. Captopril potentiated meropenem activity against MBL-producing carbapenemresistant Klebsiella pneumoniae:in vitro and in vivo study[J]. Journal of Inorganic Biochemistry, 2021,218:111381.
• [60]ERDEM F, ABULAILA A, AKTAS Z, et al. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains[J].Antimicrobial Resistance and Infection Control, 2020,9(1):70.